Atherosclerosis, Cardiovascular Diseases, Coronary Artery Disease, Myocardial Ischemia, Stroke
Conditions
Keywords
Atherosclerosis, Longitudinal, Biomarker, Coronary angiography, Follow-up, Metabolomics, Risk factor
Brief summary
The Beijing Hospital Atherosclerosis Study (BHAS) is a prospective, single-center, observational cohort study performed at the Beijing Hospital in Beijing, China. Subjects enrolled in this study will be the consecutive patients undergoing coronary angiography in the hospital. Blood samples are taken immediately before the angiographic procedure. Clinical and angiographic characteristics are recorded. All patients will have routine follow-up at 6 months and 1 year postprocedure, then yearly thereafter. Follow-up includes mortality, myocardial infarction (MI), stroke, rehospitalization, coronary revascularization procedures, life styles, and medication use. The primary end point for the study will be the major adverse cardiovascular events (MACE), defined as death from any cause, nonfatal myocardial infarction, nonfatal stroke and revascularization. This study has been reviewed and approved by the Ethics Committee of Beijing Hospital. All enrolled individuals will be received written notice of the intended use of their blood samples and provided written consent. The major objectives of the BHAS Study are to (1) establish a prospective cohort and a biological sample bank in ethnic Chinese with coronary angiography, (2) identify baseline new biosignature profiles such as novel biomarkers via metabolomics approach associated with the subsequent clinical events, (3) assess the use of molecular profiles from multiple platforms (eg, genomics, proteomics, and metabolomics) integrated with readily available clinical information for improved risk classification for cardiovascular events, and (4) provide clearer understanding of underlying disease processes.
Interventions
None listed
Sponsors
Beijing Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age \>18y * Consent for the study * Primary reason for catheterization is concern for ischemic heart disease * Complete clinical and coronary angiogram data available
Exclusion criteria
* Primary pulmonary hypertension or severe lung disease * Cardiac transplantation * Other solid organ transplant * Peripheral vascular intervention only * Right heart catheterization only * Advanced heart failure * Congenital heart disease * Women who are pregnant or nursing, or preparing for pregnant during the study period * Progressive fatal disease * History of alcoholism or drug abuse * Patients with mental illness and are being treated * Patients are undergoing radiotherapy or chemotherapy * Acute and chronic infectious diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with major adverse cardiovascular events (MACE) | 3 years | MACE include death from any cause, nonfatal myocardial infarction, nonfatal stroke and revascularization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with other atherosclerosis events | 3 years | Other atherosclerosis events include readmission for angin and transient ischemic attack. |
Countries
China
Contacts
Primary ContactRuiyue Yang, M.D.
Backup ContactWenduo Zhang, M.D.
Outcome results
None listed